Pharma & Biotech - Page 13

AstraZeneca has reported positive phase 3 results from two separate non-small cell lung cancer trials, though the wins have done little to offset a significant setback elsewhere in its pipeline. The British

Sanofi is laying off 229 employees from its acquired Blueprint Medicines business in Massachusetts as part of a post-acquisition integration process. The cuts were detailed in a state Worker Adjustment and Retraining

EyePoint Pharmaceuticals (EYPT) saw its stock collapse by more than 70% on Monday after its drug-device combination Duravyu stumbled in its first of two phase 3 trial readouts this year. The company

Quanovate Tech, Inc. has voluntarily discontinued a series of advertising claims for its Mira Fertility Monitor and Test Wands following a challenge by The Procter & Gamble Company. The challenge was brought

The debate around separating the measles, mumps and rubella vaccine has focused heavily on public health, parental choice, and vaccine policy choices. However, the pharmaceutical industry faces a distinct and urgent question

Fresenius Kabi has pulled a single batch of its biosimilar Tyenne (tocilizumab-aazg) injection in 20 ml vials following the discovery of glass particles in the product. The German-headquartered drugmaker confirmed the recall

Alfasigma has announced plans to acquire Nordic Pharma from Sever Life Sciences in a deal worth an undisclosed sum, marking its latest international expansion move. The Italian drugmaker is purchasing Nordic Pharma,

Neurocrine Biosciences is pushing back against growing safety concerns surrounding Vykat XR, its rare disease drug acquired in a $2.9 billion buyout of Soleno Therapeutics last spring. A group of clinicians with

Amgen (AMGN) faces mounting pressure over its rare disease drug Tavneos after European regulators published detailed findings underpinning their decision to revoke its marketing authorisation. The European Commission formally confirmed last week